Cirrhosis surgery

Revision as of 15:03, 5 December 2017 by Sudarshana Datta (talk | contribs)
Jump to navigation Jump to search

Cirrhosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Cirrhosis surgery On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cirrhosis surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cirrhosis surgery

CDC on Cirrhosis surgery

Cirrhosis surgery in the news

Blogs on Cirrhosis surgery

Directions to Hospitals Treating Cirrhosis

Risk calculators and risk factors for Cirrhosis surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

Overview

Typically for a patient with progressed cirrhosis of the liver, transplantation may be the only viable treatment. If transplantation is not possible or desired, a patient may undergo the TIPS procedure which has demonstrated a great deal of success.

Surgery

Transplantation

  • If the complications of cirrhosis cannot be controlled or when the liver ceases functioning, liver transplantation is necessary.
  • Survival from liver transplantation has been improving over the 1990s, and the five-year survival rate is now around 80%, depending largely on the severity of disease and medical comorbidities in the recipient.[1]
  • In the United States, the MELD score is used to prioritize patients for transplantation.[2]
  • Transplantation necessitates the use of immune suppressants (ciclosporin or tacrolimus).
Prevalence
Symptoms After Surgery
  • Complications of end stage liver disease that were present before transplantation are typically resolved after the surgery.
  • Complications such as variceal bleeding, encephalopathy, and hepatorenal syndrome are usually resolved after a successful transplantation.
  • Pruritis, which may be associated with cirrhosis, is typically cleared up post-surgery.
Survival
  • In cases in which transplantation is indicated for a patient with cirrhosis, transplantation can have a significant effect on the long term survival of the patient.
  • The overall survival rates of patients have demonstrated a significant increase in patients post transplantation. The overall survival rate at 1 year post surgery is 87%, at 5 years post surgery is 80%, and at 10 years post surgery is 67%.[4]

TIPS (Transjugular Intrahepatic Portosystemic Shunt)

  • A transjugular intrahepatic portosystemic shunt, also TIPS, is an artificial channel in the liver from the portal vein to a hepatic vein (for blood). It is created endovascularly via the jugular vein.
  • The main purpose of the TIPS procedure is to decompress the portal vein which would in turn help to prevent rebleeding from varices, and also prevent ascites formation.[5]
Indications
  • TIPS is used to treat portal hypertension which is often due to cirrhosis.
  • The scar tissue in the liver due to cirrhosis causes blockages in the portal vein, leading to portal vein hypertension.
  • Due to the increased pressure in the portal vein, veins that are bypassing the liver may rupture. The possibility of rupture makes a transjugular intrahepatic portosystemic shunt a beneficial procedure.
Contraindications
Survival
  • TIPS procedure appears to be a safe option for people with portal hypertension due to cirrhosis. The TIPS procedure has a 30-day mortality rate of 45% for people that need an emergency portacaval shunt.[6]
  • The mortality rate due to the TIPS procedure itself is less than 2%.
  • Some of the causes of death associated with TIPS include myocardial infarctions during the procedure as well as an intraperitoneal hemorrhage due to a rupture or puncture of the portal vein.[6] These complications are rare and many of the people that die from this procedure have some sort of bleeding occurring before the procedure even begins.[6]
Complications

Although the TIPS procedure is a less invasive alternate to transplantation, there are some complications that may be present. Complications involving the puncture of the portal vein have been previously noted. It is possible for there to be hemorrhage or hematoma from the puncture site.[6] There are also complications associated with the dilation of the portal vein. There is a high likelihood of death if this portion of the procedure does not go correctly.[6] There is also a possibility of there being thrombosis of the stent that is placed in the hepatic vein during the procedure.[6]

If the patient going through the TIPS procedure is in line for a liver transplantation, this can further complicate the procedure. Inserting a shunt into the liver needs to be exceedingly precise in patients that have the possibility of obtaining a new liver. In transplant cases, it has been shown in some studies that the patient and graft survival was somewhat worse in those individuals that previously had a shunt placed in the hepatic vein.[5] It is typically more difficult to perform the transplantation after a patient has already undergone the TIPS procedure.

Drawbacks

Two of the major weaknesses that can be present with the TIPS procedure are stent dysfunction and portosystemic encephalopathy.[7] A problem also arises due to the fact that there is a frequent need for endovascluar reintervention to make sure that the stent remains patent.[7]

References

  1. liver transplant outlook and survival rates
  2. Cosby RL, Yee B, Schrier RW (1989). "New classification with prognostic value in cirrhotic patients". Mineral and electrolyte metabolism. 15 (5): 261–6. PMID 2682175.
  3. Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N (2007). "Transplantation trends in primary biliary cirrhosis". Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 5 (11): 1313–5. doi:10.1016/j.cgh.2007.07.015. PMID 17900996. Retrieved 2012-09-06. Unknown parameter |month= ignored (help)
  4. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J (2001). "Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center". Hepatology (Baltimore, Md.). 33 (1): 22–7. doi:10.1053/jhep.2001.20894. PMID 11124816. Retrieved 2012-09-06. Unknown parameter |month= ignored (help)
  5. 5.0 5.1 5.2 5.3 Boyer TD, Haskal ZJ (2005). "The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension". Hepatology (Baltimore, Md.). 41 (2): 386–400. doi:10.1002/hep.20559. PMID 15660434. Retrieved 2012-09-06. Unknown parameter |month= ignored (help)
  6. 6.0 6.1 6.2 6.3 6.4 6.5 Freedman AM, Sanyal AJ, Tisnado J, Cole PE, Shiffman ML, Luketic VA, Purdum PP, Darcy MD, Posner MP (1993). "Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review". Radiographics : a Review Publication of the Radiological Society of North America, Inc. 13 (6): 1185–210. PMID 8290720. Retrieved 2012-09-06. Unknown parameter |month= ignored (help)
  7. 7.0 7.1 Colombato L (2007). "The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension". Journal of Clinical Gastroenterology. 41 Suppl 3: S344–51. doi:10.1097/MCG.0b013e318157e500. PMID 17975487. Retrieved 2012-09-06.

Template:WH Template:WS